Pharma Mar Statistics
Total Valuation
Pharma Mar has a market cap or net worth of 1.54 billion. The enterprise value is 1.43 billion.
| Market Cap | 1.54B |
| Enterprise Value | 1.43B |
Important Dates
The next estimated earnings date is Friday, February 27, 2026.
| Earnings Date | Feb 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 17.21M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 12.04% |
| Owned by Institutions (%) | 9.50% |
| Float | 13.29M |
Valuation Ratios
The trailing PE ratio is 38.69 and the forward PE ratio is 25.29.
| PE Ratio | 38.69 |
| Forward PE | 25.29 |
| PS Ratio | 7.34 |
| PB Ratio | 6.66 |
| P/TBV Ratio | 6.70 |
| P/FCF Ratio | 78.69 |
| P/OCF Ratio | 61.95 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 41.44, with an EV/FCF ratio of 72.87.
| EV / Earnings | 35.83 |
| EV / Sales | 6.72 |
| EV / EBITDA | 41.44 |
| EV / EBIT | 54.76 |
| EV / FCF | 72.87 |
Financial Position
The company has a current ratio of 2.73, with a Debt / Equity ratio of 0.25.
| Current Ratio | 2.73 |
| Quick Ratio | 2.03 |
| Debt / Equity | 0.25 |
| Debt / EBITDA | 1.73 |
| Debt / FCF | 3.01 |
| Interest Coverage | 5.23 |
Financial Efficiency
Return on equity (ROE) is 17.91% and return on invested capital (ROIC) is 19.47%.
| Return on Equity (ROE) | 17.91% |
| Return on Assets (ROA) | 4.08% |
| Return on Invested Capital (ROIC) | 19.47% |
| Return on Capital Employed (ROCE) | 8.71% |
| Weighted Average Cost of Capital (WACC) | 6.68% |
| Revenue Per Employee | 420,688 |
| Profits Per Employee | 79,796 |
| Employee Count | 500 |
| Asset Turnover | 0.53 |
| Inventory Turnover | 0.19 |
Taxes
| Income Tax | -10.66M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -7.38% in the last 52 weeks. The beta is 0.44, so Pharma Mar's price volatility has been lower than the market average.
| Beta (5Y) | 0.44 |
| 52-Week Price Change | -7.38% |
| 50-Day Moving Average | 72.14 |
| 200-Day Moving Average | 72.07 |
| Relative Strength Index (RSI) | 51.02 |
| Average Volume (20 Days) | 1,581 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Pharma Mar had revenue of 210.34 million and earned 39.90 million in profits. Earnings per share was 2.29.
| Revenue | 210.34M |
| Gross Profit | 198.85M |
| Operating Income | 25.81M |
| Pretax Income | 29.24M |
| Net Income | 39.90M |
| EBITDA | 31.62M |
| EBIT | 25.81M |
| Earnings Per Share (EPS) | 2.29 |
Balance Sheet
The company has 172.08 million in cash and 59.05 million in debt, with a net cash position of 113.04 million.
| Cash & Cash Equivalents | 172.08M |
| Total Debt | 59.05M |
| Net Cash | 113.04M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 231.74M |
| Book Value Per Share | 13.29 |
| Working Capital | 180.63M |
Cash Flow
In the last 12 months, operating cash flow was 24.92 million and capital expenditures -5.30 million, giving a free cash flow of 19.62 million.
| Operating Cash Flow | 24.92M |
| Capital Expenditures | -5.30M |
| Free Cash Flow | 19.62M |
| FCF Per Share | n/a |
Margins
Gross margin is 94.53%, with operating and profit margins of 12.27% and 18.97%.
| Gross Margin | 94.53% |
| Operating Margin | 12.27% |
| Pretax Margin | 13.90% |
| Profit Margin | 18.97% |
| EBITDA Margin | 15.03% |
| EBIT Margin | 12.27% |
| FCF Margin | 9.33% |
Dividends & Yields
Pharma Mar does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 41.02% |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | 2.58% |
| FCF Yield | 1.27% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Pharma Mar has an Altman Z-Score of 7.86 and a Piotroski F-Score of 7.
| Altman Z-Score | 7.86 |
| Piotroski F-Score | 7 |